Research programme: IgE monoclonal antibody therapeutics - OncoQuest

Drug Profile

Research programme: IgE monoclonal antibody therapeutics - OncoQuest

Alternative Names: anti-MUC1 IgE antibody; anti-PSA monoclonal IgE; Monoclonal IgE for solid tumor immunotherapy - Quest PharmaTech

Latest Information Update: 24 Oct 2016

Price : $50

At a glance

  • Originator Advanced Immune Therapeutics
  • Developer OncoQuest; University of California at Los Angeles
  • Class Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; IgE receptor modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 20 Oct 2016 IgE monoclonal antibody therapeutics is still in preclinical trials for Cancer, Solid tumours and Prostate cancer in USA
  • 22 Mar 2016 IgE monoclonal antibody therapeutics licensed to Shenzhen Hepalink Pharmaceutical in China
  • 07 Nov 2013 Quest PharmaTech licenses anti-MUC1 IgE technology from Stanford University
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top